Jonathan B. Greer

Jonathan B. Greer

Auto-generated profile, based on publicly available information

Jonathan B. Greer

Department of Surgery, Massachusetts General Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBEliza W Beal
Eliza W Beal
LSLorena P. Suarez-Kelly
Lorena P. Suarez-Kelly
CKCharles W. Kimbrough
Charles W. Kimbrough
Fabian M. JohnstonFabian M. Johnston
Fabian M. Johnston
JGJonathan Greer
Jonathan Greer
JCJordan Cloyd
Jordan Cloyd
Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.

28 January 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
BKBoateng Kubi
Boateng Kubi
RNRichard Nudotor
Richard Nudotor
NFNadege Fackche
Nadege Fackche
WNWasay Nizam
Wasay Nizam
JCJordan M. Cloyd
Jordan M. Cloyd
JGJonathan B. Greer
Jonathan B. Greer

3 January 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AIAlexandra C. Istl
Alexandra C. Istl
MGMichele M. Gage
Michele M. Gage
JEJesus Esquivel
Jesus Esquivel
Nita AhujaNita Ahuja
Nita Ahuja
JGJonathan B. Greer
Jonathan B. Greer
Fabian M. JohnstonFabian M. Johnston
Fabian M. Johnston


1 February 2022 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
WNWasay Nizam
Wasay Nizam
NFNadege Fackche
Nadege Fackche
BPBernardo Pessoa
Bernardo Pessoa
BKBoateng Kubi
Boateng Kubi
JCJordan M. Cloyd
Jordan M. Cloyd
JGJonathan B. Greer
Jonathan B. Greer

25 February 2021 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
NFNadege Fackche
Nadege Fackche
RSRyan K. Schmocker
Ryan K. Schmocker
BKBoateng Kubi
Boateng Kubi
JCJordan M. Cloyd
Jordan M. Cloyd
AAAhmed Ahmed
Ahmed Ahmed
JGJonathan B. Greer
Jonathan B. Greer